| Average Maternal-Newborn Payment for Study Population with the Hem-Avert Device (Investigational Group) |
| Type of birth |
No. of patients |
Avg. insurer payment ($) |
Total payment for group ($) |
| Cesarean |
6 |
24,949 |
149,694 |
| Vaginal |
44 |
15,931 |
700,964 |
| Total Commercial Insurer Payment for Investigational Group: $850,658 |
| Average Commercial Insurer Payment per Patient: $17,013 |
|
| Average Maternal-Newborn Payment for Study Population without Hem-Avert Device (Control Group) |
| Type of birth |
No. of patients |
Avg. insurer payment ($) |
Total payment for group ($) |
| Cesarean |
19 |
24,949 |
474,031 |
| Vaginal |
29 |
15,931 |
461,999 |
| Total Commercial Insurer Payment for Control Group: $936,030 |
| Average Commercial Insurer Payment per Patient: $19,500 |
|
| Table 3: Potential Cost Offsets from Use of Hem-Avert Device–Commercial
Insurers. |
